SLC5A2 and chronic kidney disease: The advent of sodium-glucose 2 transporter (SGLT2) inhibitors offers the opportunity to substantially retard DKD progression and ameliorate the development of cardiovascular disease burden, with greater benefit being derived from earlier intervention facilitated by referral at lower CKD stages [52].